Enrico Regalia

Enrico Regalia

Auto-generated profile, based on publicly available information

Enrico Regalia

Hepato-Pancreato-Biliary Surgery and Liver Transplant Unit, Istituto Nazionale Tumori, Istituto di Ricovero e Cura a Carattere Scientifico, Milan, Italy

Research Focus & Metrics

Academic Career Length

41Years (1986-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 March 1996 in New England Journal of Medicine
Verified
Journal Article
Open access
PDF file
VMVincenzo Mazzaferro
Vincenzo Mazzaferro
EREnrico Regalia
Enrico Regalia
RDRoberto Doci
Roberto Doci
SASalvatore Andreola
Salvatore Andreola
APAndrea Pulvirenti
Andrea Pulvirenti
LGLeandro Gennari
Leandro Gennari
The role of orthotopic liver transplantation in the treatment of patients with cirrhosis and hepatocellular carcinoma is controversial, and determining which patients are likely to have a good outcome after liver transplantation is difficult.

1 November 2004 in Annals of Surgery
Verified
Journal Article
Closed access
VMVincenzo Mazzaferro
Vincenzo Mazzaferro
CBCarlo Battiston
Carlo Battiston
SPStefano Perrone
Stefano Perrone
APAndrea Pulvirenti
Andrea Pulvirenti
EREnrico Regalia
Enrico Regalia
SASalvatore Andreola
Salvatore Andreola
Objective: Determine the histologic response-rate (complete versus partial tumor extinction) after single radiofrequency ablation (RFA) of small hepatocellular carcinoma (HCC) arising in cirrhosis. Investigate possible predictors of response and assess efficacy and safety of RFA as a bridge to liver transplantation (OLT). Background: RFA has become the elective treatment of local control of HCC, although histologic data supporting radiologic assessment of response are rare and prospective studies are lacking. Prognostic impact of repeated RFA for HCC persistence is also undetermined. Methods: Percentage of RFA-induced necrosis and tumor persistence-rate at various intervals from treatment was studied in 60 HCC (median: 3 cm; Milan-Criteria IN: 80%) isolated in 50 consecutive cirrhotic patients undergoing OLT. Single-session RFA was the only treatment planned before OLT. Histologic response determined on explanted livers was related to 28 variables and to pre-OLT CT scan. Results: Mean interval RFA→OLT was 9.5 months. Post-RFA complete response rate was 55%, rising to 63% for HCC ≤3 cm. Tumor size was the only prognostic factor significantly related to response (P = 0.007). Tumor satellites and/or new HCC foci (56 nodules) were unaffected by RFA and significantly correlated with HCC >3 cm (P = 0.05). Post-RFA tumor persistence probability increased with time (12 months: 59%; 18 months: 70%). Radiologic response rate was 70%, not significantly different from histology. Major post-RFA morbidity was 8%. No mortality, Child deterioration, patient withdrawal because of tumor progression was observed. Post-OLT 3-year patient/graft survival was 83%. Conclusions: RFA is a safe and effective treatment of small HCC in cirrhotics awaiting OLT, although tumor size (>3 cm) and time from treatment (>1 year) predict a high risk of tumor persistence in the targeted nodule. RFA should not be considered an independent therapy for HCC.

1 May 2016 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
VMVincenzo Mazzaferro
Vincenzo Mazzaferro
CSCarlo Sposito
Carlo Sposito
JCJorgelina Coppa
Jorgelina Coppa
RMR. Miceli
R. Miceli
SBS. Bhoori
S. Bhoori
LMLuigi Mariani
Luigi Mariani
Selection criteria and benefit of liver transplantation for hepatic metastases from neuroendocrine tumors (NETs) remain uncertain. Eighty‐eight consecutive patients with metastatic NETs eligible for liver transplantation according to Milan‐NET criteria were offered transplant (n = 42) versus nontransplant options (n = 46) depending on list dynamics, patient disposition, and age. Tumor burden between groups did not differ. Transplant patients were younger (40.5 vs. 55.5 years; p < 0.001). Long‐term outcomes were compared after matching between groups made on multiple Cox models adjusted for propensity score built on logistic models. Survival benefit was the difference in mean survival between transplant versus nontransplant options. No patients were lost or died without recurrence. Median follow‐up was 122 months. The transplant group showed a significant advantage over nontransplant strategies at 5 and 10 years in survival (97.2% and 88.8% vs. 50.9% and 22.4%, respectively; p < 0.001) and time‐to‐progression (13.1% and 13.1% vs. 83.5% and 89%; p < 0.001). After adjustment for propensity score, survival advantage of the transplant group was significant (hazard ratio = 7.4; 95% confidence interval (CI): 2.4–23.0; p = 0.001). Adjusted transplant‐related survival benefit was 6.82 months (95% CI: 1.10–12.54; p = 0.019) and 38.43 months (95% CI: 21.41–55.45; p < 0.001) at 5 and 10 years, respectively. Liver transplantation for metastatic NETs under restrictive criteria provides excellent long‐term outcome. Transplant‐related survival benefit increases over time and maximizes after 10 years.

8 April 1998 in Journal of Hepato-Biliary-Pancreatic Surgery
Verified
Journal Article
Closed access
PDF file
EREnrico Regalia
Enrico Regalia
LFLuigi Rainero Fassati
Luigi Rainero Fassati
UVUmberto Valente
Umberto Valente
APAndrea Pulvirenti
Andrea Pulvirenti
IDIsabella Damilano
Isabella Damilano
VMVincenzo Mazzaferro
Vincenzo Mazzaferro

15 July 1998 in Cancer
Verified
Journal Article
Open access
PDF file
EBEmilio Bajetta
Emilio Bajetta
Lorenza RimassaLorenza Rimassa
Lorenza Rimassa
CCCarlo Carnaghi
Carlo Carnaghi
ESEttore Seregni
Ettore Seregni
LFLeonardo Ferrari
Leonardo Ferrari
LMLuigi Mariani
Luigi Mariani
BACKGROUND For patients with surgically untreatable neuroendocrine tumors (NETs), the optimal therapeutic approach remains undefined. Somatostatin analogs and interferons have failed to control neoplastic growth, and chemotherapy has been only moderately more effective. The authors' previous study of the combination of 5‐fluorouracil (FU), dacarbazine (DTIC), and epirubicin (EPI) (the FDE regimen) documented good tolerability, but the results for tumor growth control were disappointing. In an attempt to improve these results, the authors conducted a preliminary trial of an intensified FDE regimen (FU 500 mg/m2 administered intravenously [i.v.], DTIC 200 mg/m2 i.v., and EPI 30 mg/m2 i.v. on Days 1, 2, and 3 every 3 weeks). METHODS Thirty NET patients (15 male, 15 female; median age, 55 years; age range, 19‐72 years) were enrolled, none of whom had previously been given chemotherapy. The histologic types of disease were gastroenteropancreatic (GEP) tumors (n = 21, 6 carcinoid tumors and 15 pancreatic NETs), other carcinoid tumors (n = 3), other NETs (n = 4), medullary thyroid carcinoma (MTC) (n = 1), and Merkel cell carcinoma (n = 1). Six patients had a syndrome related to endocrine hypersecretion. One hundred fifty‐four therapy cycles were delivered (median, six per patient), and all patients could be evaluated for response on the basis of intent‐to‐treat analysis. RESULTS There were 9 objective responses: 2 complete responses (in 1 patient with Merkel cell carcinoma and 1 with pancreatic NET) and 7 partial responses (in 3 patients with pancreatic NETs, 2 with other NETs, 1 with GEP carcinoid tumor, and 1 with MTC). The median duration of response was 10 months (range, 5+ to 24+ months). No reduction in symptoms was achieved among the six patients with endocrine hypersecretion syndrome. Levels of urinary 5‐hydroxyindoleacetic acid and serum chromogranin A were decreased in 50% and 14% of patients, respectively, who presented with abnormal baseline values. Treatment toxicity was acceptable and included nausea and vomiting, alopecia, leukopenia, and mucositis. CONCLUSIONS This trial demonstrated that the FDE regimen may be at least as effective as other systemic regimens. Comparison of this experience with the authors' previous trial revealed a noteworthy increase in the activity of the intensified regimen, especially in GEP NETs (the most chemoresistant tumors). Continued clinical research to improve these results is highly justified. Cancer 1998;83:372‐378. © 1998 American Cancer Society.

1 March 2000 in Hepatology
Verified
Journal Article
Open access
PDF file
GPGianluca Perseghin
Gianluca Perseghin
VMVincenzo Mazzaferro
Vincenzo Mazzaferro
LSLucia Piceni Sereni
Lucia Piceni Sereni
EREnrico Regalia
Enrico Regalia
SBStefano Benedini
Stefano Benedini
Livio LuziLivio Luzi
Livio Luzi
Diabetes mellitus frequently complicates cirrhosis but the pathogenic mechanisms are unknown. To assess the contribution of reduced insulin action and secretion, 24 cirrhotic-diabetic patients waiting for liver transplant because of an unresectable hepatocarcinoma underwent an oral glucose tolerance test (OGTT) to assess the β-cell function and an insulin clamp combined with [3-3H]glucose infusion to measure whole body glucose metabolism before and 2 years after the transplant. Seven cirrhotic nondiabetic patients, 11 patients with chronic uveitis on similar immunosuppressive therapy, and 7 healthy subjects served as control groups. Cirrhotic patients showed a profound insulin resistance, and diabetics in addition also showed increased endogenous glucose production (P < .05) and insulin deficiency during the OGTT (P < .05). Liver transplantation normalized endogenous glucose production and insulin sensitivity but failed to cure diabetes in 8 of the 24 patients because a markedly low insulin response during the OGTT. Age, body mass index, family history of diabetes, immunosuppressive drugs, and pathogenesis of cirrhosis did not predict in whom liver transplant was going to cure diabetes. On the contrary, a reduced secretory response characterized the patients in whom the transplant would not be curative. In summary, insulin resistance was a primary event complicating cirrhosis but additional β-cell secretory defects were crucial for development of diabetes. Liver transplantation, lessening insulin resistance, cured hepatogenous diabetes in 67% of cirrhotic-diabetic patients; nevertheless 33% were still diabetics because the persistence of a reduced β-cell function, which makes these patients eventually eligible for combined islet transplantation.